SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:liu-181065"
 

Sökning: onr:"swepub:oai:DiVA.org:liu-181065" > Cardiovascular even...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005431naa a2200685 4500
001oai:DiVA.org:liu-181065
003SwePub
008211118s2022 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-1810652 URI
0247 a https://doi.org/10.1111/cts.131682 DOI
040 a (SwePub)liu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Jung, Se Yongu Yonsei Univ, South Korea4 aut
2451 0a Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database
264 c 2021-10-31
264 1b Wiley,c 2022
338 a electronic2 rdacarrier
500 a Funding Agencies|Yonsei University College of Medicine for 2021 [2021-32-0049] Funding Source: Medline
520 a On October 2020, the US Food and Drug Administration (FDA) approved remdesivir as the first drug for the treatment of coronavirus disease 2019 (COVID-19), increasing remdesivir prescriptions worldwide. However, potential cardiovascular (CV) toxicities associated with remdesivir remain unknown. We aimed to characterize the CV adverse drug reactions (ADRs) associated with remdesivir using VigiBase, an individual case safety report database of the World Health Organization (WHO). Disproportionality analyses of CV-ADRs associated with remdesivir were performed using reported odds ratios and information components. We conducted in vitro experiments using cardiomyocytes derived from human pluripotent stem cell cardiomyocytes (hPSC-CMs) to confirm cardiotoxicity of remdesivir. To distinguish drug-induced CV-ADRs from COVID-19 effects, we restricted analyses to patients with COVID-19 and found that, after adjusting for multiple confounders, cardiac arrest (adjusted odds ratio [aOR]: 1.88, 95% confidence interval [CI]: 1.08-3.29), bradycardia (aOR: 2.09, 95% CI: 1.24-3.53), and hypotension (aOR: 1.67, 95% CI: 1.03-2.73) were associated with remdesivir. In vitro data demonstrated that remdesivir reduced the cell viability of hPSC-CMs in time- and dose-dependent manners. Physicians should be aware of potential CV consequences following remdesivir use and implement adequate CV monitoring to maintain a tolerable safety margin.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Andra medicinska och farmaceutiska grundvetenskaper0 (SwePub)301992 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Other Basic Medicine0 (SwePub)301992 hsv//eng
7001 a Kim, Min Seou Korea Univ, South Korea; Sungkyunkwan Univ, South Korea4 aut
7001 a Li, Hanu Univ Florida, FL USA4 aut
7001 a Lee, Keum Hwau Yonsei Univ, South Korea4 aut
7001 a Koyanagi, Aiu Univ Barcelona, Spain; ICREA, Spain; Inst Salud Carlos III, Spain4 aut
7001 a Solmi, Marcou Univ Ottawa, Canada; Ottawa Hosp, Canada; Univ Ottawa, Canada4 aut
7001 a Kronbichler, Andreasu Med Univ Innsbruck, Austria4 aut
7001 a Dragioti, Elenau Linköpings universitet,Avdelningen för prevention, rehabilitering och nära vård,Medicinska fakulteten,Region Östergötland, Smärt och rehabiliteringscentrum4 aut0 (Swepub:liu)eledr71
7001 a Tizaoui, Kalthoumu Tunis El Manar Univ, Tunisia4 aut
7001 a Cargnin, Sarahu Univ Piemonte Orientale, Italy4 aut
7001 a Terrazzino, Salvatoreu Univ Piemonte Orientale, Italy4 aut
7001 a Hong, Sung Hwiu Yonsei Univ, South Korea4 aut
7001 a Abou Ghayda, Ramyu Univ Hosp, OH USA; Case Western Reserve Univ, OH 44106 USA4 aut
7001 a Kim, Nam Kyunu Emory Univ, GA 30322 USA; Yonsei Univ, South Korea4 aut
7001 a Chung, Seo Kyoungu Ewha Womans Univ, South Korea4 aut
7001 a Jacob, Louisu Univ Barcelona, Spain; Univ Versailles St Quentin En Yvelines, France4 aut
7001 a Salem, Joe-Elieu Sorbonne Univ, France4 aut
7001 a Yon, Dong Keonu Seoul Natl Univ, South Korea4 aut
7001 a Lee, Seung Wonu Sejong Univ, South Korea4 aut
7001 a Kostev, Karelu Univ Clin Marburg, Germany4 aut
7001 a Kim, Ah Youngu Yonsei Univ, South Korea4 aut
7001 a Jung, Jo Wonu Yonsei Univ, South Korea4 aut
7001 a Choi, Jae Youngu Yonsei Univ, South Korea4 aut
7001 a Shin, Jin Soou Korea Res Inst Chem Technol, Germany4 aut
7001 a Park, Soon-Jungu T&R Biofab Co Ltd, Germany4 aut
7001 a Choi, Seong Woou Seoul Natl Univ, South Korea4 aut
7001 a Ban, Kiwonu City Univ Hong Kong, Peoples R China4 aut
7001 a Moon, Sung-Hwanu T&R Biofab Co Ltd, Germany4 aut
7001 a Go, Yun Youngu City Univ Hong Kong, Peoples R China4 aut
7001 a Shin, Jae Ilu Yonsei Univ, South Korea4 aut
7001 a Smith, Leeu Anglia Ruskin Univ, England4 aut
7102 a Yonsei Univ, South Koreab Korea Univ, South Korea; Sungkyunkwan Univ, South Korea4 org
7730 t Clinical and Translational Scienced : Wileyg 15:2, s. 501-513q 15:2<501-513x 1752-8054x 1752-8062
8564 u https://liu.diva-portal.org/smash/get/diva2:1612465/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 u https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cts.13168
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-181065
8564 8u https://doi.org/10.1111/cts.13168

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy